Cross-Sector entity
Namit Joshi is most often covered alongside India, which appears in 3 of these 5 stories. Across a 17-day span, the pace is roughly 2.1 stories per week. The busiest single day carried 2. Coverage clusters in pharma, which accounts for 2 of those 5, with the remainder spread across 3 other categories.
5 verified stories tracked
Last mentioned: Aug 12, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 20 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Namit Joshi is most often covered alongside India, which appears in 3 of these 5 stories. Across a 17-day span, the pace is roughly 2.1 stories per week. The busiest single day carried 2. Coverage clusters in pharma, which accounts for 2 of those 5, with the remainder spread across 3 other categories. Negative sentiment appears in 40% of the tracked stories. This profile follows 5 Cross-Sector stories mentioning Namit Joshi across the period from July 27, 2026 to August 12, 2026. Each carries 2 original sources on average.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Namit Joshi. Shared-story counts are live from our verified record — not editorial picks.
India's pharma exports grew 6.8% to $8.1B in Q1 FY27, with the US absorbing $2.5B at a 30.89% share — trade and earnings data that shapes the outlook for Indian healthcare exporters and investors.
India's vaccine exports jumped 35.68% to $390M in Q1 FY27 amid $8.1B in total pharma shipments, strengthening the country's role as a supplier of affordable vaccines and generics to global health systems.
Source: moneycontrol.com · calcuttanews.net
A proposed US tariff of up to 200% on generic drug imports threatens to sever the supply of affordable medicines from India, potentially causing shortages and billions in added costs for hospitals and patients. Industry experts warn that manufacturers cannot absorb the tariffs and may exit the US market, directly undermining efforts to control healthcare spending.
The proposed US tariff on generic drugs—jumping to 200%—poses an existential threat to Indian pharmaceutical companies that have long dominated the American market. With margins razor-thin and a 4-5 year timeline needed to onshore production, industry leaders call the plan 'completely out of scope,' potentially forcing a major restructuring of global generic supply chains.
Source: heraldglobe.com · milwaukeesun.com
The zero-tariff India-UK trade pact propels Indian pharmaceutical exports to a projected $981M, offering biotech and pharma firms expanded market access, lower costs, and new collaboration channels in R&D and manufacturing.
Source: indiagazette.com · britainnews.net
